NervGen Engages Vorticom Inc. to Provide Media Relations Services
Vancouver, Canada. June 25, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engaged Vorticom Inc. (“Vorticom”), a New York based full-service public relations agency to provide media relations and […]
The Outdoor Diaries: Rediscovering a Love of the Ocean – A Story of Adapted Surfing
By Codi Darnell June 22, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. Imagine your favourite place – the […]
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer’s Disease Models / NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer’s Disease
Vancouver, Canada. June 10, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research agreement with Sylics Contract Research (“Sylics”), a contract research organization specializing in testing […]
Life, Love and Alzheimer’s – A Daughter’s Perspective
By Codi Darnell June 8, 2021 The dynamic of a child-parent relationship is one that shifts many times over a lifetime. It twists and turns as children become adults and parents go from hero to human. It’s in your twenties when you start to discover who your parents are as people beyond their Mom and […]
NervGen Pharma Reports First Quarter 2021 Results
Vancouver, Canada. May 20, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. “We achieved several key milestones in the first […]
The Outdoor Diaries: Handcycling Into the Forest
By Codi Darnell May 25, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. The world is full of natural […]
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Vancouver, Canada. May 12, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced that it has closed its previously announced overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”). Pursuant to […]
Adding Diverse Voices to the MS Conversation
By Codi Darnell May 11, 2021 Inclusion, diversity, representation – these words are everywhere. We are living through a time of social change where people of all backgrounds are not only working to be seen and accepted but are being sought out to give their perspectives. From POC and those in the LGBTQ+ community to […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. May 7, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to an Officer of the Company exercisable at a price of […]
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Vancouver, Canada. May 6, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the Company’s Phase 1 clinical trial in […]